Cereno’s CEO: “CS014 adds potential for cardiovascular disease patients”
Cereno Scientific is a biotech company developing treatments for the number one killer in the world – cardiovascular disease.
The company has been granted the approval from EMA to initiate a first-in-human phase I trial with candidate CS014 – a novel epigenetic HDAC inhibitor.